Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.

Published

Journal Article

Although glycemic control is an important and effective way to prevent and minimize the worsening of diabetes-related complications, type 2 diabetes is a progressive disease which often proves difficult to manage. Most affected patients will eventually require therapy with multiple medications in order to reach appropriate glycemic targets. The dipeptidyl peptidase-4 (DPP-4) inhibitors constitute a relatively new class of oral medications for the treatment of type 2 diabetes, which has become widely incorporated into clinical practice. This review summarizes the available data on the efficacy, safety, and tolerability of these medications.

Full Text

Duke Authors

Cited Authors

  • Cox, ME; Rowell, J; Corsino, L; Green, JB

Published Date

  • 2010

Published In

Volume / Issue

  • 2 /

Start / End Page

  • 7 - 19

PubMed ID

  • 21701614

Pubmed Central ID

  • 21701614

Electronic International Standard Serial Number (EISSN)

  • 1179-1365

Language

  • eng

Conference Location

  • New Zealand